Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Methylnaltrexone Bromide

    Client Email Product

    Methylnaltrexone Bromide

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    RELATED EXCIPIENT COMPANIES

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    9
    US DMFs Filed

    US DMFs Filed

    6
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    4
    API REF. PRICE (USD / KG)
    9,034

    API Market Place

    2
    INTERMEDIATES
    1
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    6
    Europe

    Europe

    6
    Canada

    Canada

    1
    Australia

    Australia

    2
    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    409.00

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS
    2
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    33

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    31
    REF STANDARD

    EDQM

    0

    USP

    2

    JP

    0

    Other Listed Suppliers

    1
    SERVICES

    0

    Full View ScreenFull Screen View
    Salix Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R)
    Salix Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R)

    https://www.accesswire.com/839567/salix-pharmaceuticals-announces-a-phase-2-investigator-initiated-study-of-relistor-methylnaltrexone-bromide-mntx-in-patients-with-resectable-head-and-neck-squamous-cell-carcinoma

    ACCESSWIRE
    06 Mar 2024
    Share Share
    Gland's Generic Methylnaltrexone Bromide Receives Receives Approval in the U.S.
    Gland's Generic Methylnaltrexone Bromide Receives Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216836

    FDA
    05 May 2023
    Share Share
    Noramco Announces Submission & Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide
    Noramco Announces Submission & Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide

    https://www.noramco.com/2022/11/01/noramco-announces-submission-and-reactivation-of-the-drug-master-file-for-active-pharmaceutical-ingredient-methylnaltrexone-bromide/

    PRESS RELEASE
    01 Nov 2022
    Share Share
    Salix Will Present XIFAXAN(R, TRULANCE and RELISTOR Data at Scientific Meeting
    Salix Will Present XIFAXAN(R, TRULANCE and RELISTOR Data at Scientific Meeting

    https://www.accesswire.com/721607/Salix-Will-Present-XIFAXANR-Rifaximin-TRULANCER-Plecanatide-and-RELISTORR-Methylnaltrexone-Bromide-Data-at-The-American-College-of-GastroenterologyR-2022-Annual-Scientific-Meeting

    ACCESSWIRE
    24 Oct 2022
    Share Share
    New Data on Cost Impact of Treating OIC with FDA-Approved Medications
    New Data on Cost Impact of Treating OIC with FDA-Approved Medications

    https://www.prnewswire.com/news-releases/new-data-on-cost-impact-of-treating-opioid-induced-constipation-oic-with-fda-approved-medications-including-salixs-relistor-subcutaneous-injection-methylnaltrexone-bromide-in-the-emergency-department-is-published-in-advanc-301509600.html

    PRNEWSWIRE
    24 Mar 2022
    Share Share
    Aegerion's Biologic Myalept (Metreleptin) Receives Approval in the U.S.
    Aegerion's Biologic Myalept (Metreleptin) Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125390

    FDA
    28 Feb 2022
    Share Share
    Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At PAINWeek 2021
    Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At PAINWeek 2021

    https://www.prnewswire.com/news-releases/salix-will-share-relistor-methylnaltrexone-bromide-data-at-painweek-2021-301368004.html

    PRNEWSWIRE
    02 Sep 2021
    Share Share
    Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data Analysis at the 2021
    Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data Analysis at the 2021

    https://finance.yahoo.com/finance/news/salix-share-relistor-methylnaltrexone-bromide-120200703.html

    YAHOO
    03 Jun 2021
    Share Share
    Salix To Highlight New Data Across Its Portfolio Products At Digestive Disease
    Salix To Highlight New Data Across Its Portfolio Products At Digestive Disease

    https://www.prnewswire.com/news-releases/salix-to-highlight-new-data-across-its-portfolio-of-products-at-digestive-disease-week-2020-virtual-meeting-301049876.html

    PRNEWSWIRE
    30 Apr 2020
    Share Share
    Court upholds validity of patent protecting Relistor tablets
    Court upholds validity of patent protecting Relistor tablets

    https://www.thepharmaletter.com/in-brief/brief-court-upholds-validity-of-patent-protecting-relistor-tablets

    THE PHARMALETTER
    19 Jul 2019
    Share Share
    Salix Announces 2 Methylnaltrexone Poster for Opioid-Induced Constipation
    Salix Announces 2 Methylnaltrexone Poster for Opioid-Induced Constipation

    https://www.prnewswire.com/news-releases/salix-announces-two-methylnaltrexone-poster-presentations-for-opioid-induced-constipation-at-the-annual-assembly-of-the-american-academy-of-hospice-and-palliative-medicine-and-hospice-and-palliative-nurses-association-300811677.html

    PR NEWSWRE
    13 Mar 2019
    Share Share
    Aegerion's Metreleptin Receives Supplemental Approval in US
    Aegerion's Metreleptin Receives Supplemental Approval in US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125390

    FDA
    21 Dec 2018
    Share Share
    Aegerion Pharmaceuticals BV's Myalepta(metreleptin) Receives Approval in Europe
    Aegerion Pharmaceuticals BV's Myalepta(metreleptin) Receives Approval in Europe

    http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004218/WC500253136.pdf

    EMA
    07 Aug 2018
    Share Share
    Myalepta receives EU marketing nod to treat generalized & partial lipodystrophy
    Myalepta receives EU marketing nod to treat generalized & partial lipodystrophy

    http://www.pharmabiz.com/NewsDetails.aspx?aid=110354&sid=2

    PHARMABIZ
    02 Aug 2018
    Share Share
    Aegerion’s Myalepta Approved in Europe for Pts with Lipodystrophy
    Aegerion’s Myalepta Approved in Europe for Pts with Lipodystrophy

    https://www.businesswire.com/news/home/20180731005522/en/Aegerion%E2%80%99s-Myalepta%C2%AE%E2%96%BC-Approved-Europe-Treatment-Patients-Ultra-Rare

    BUSINESSWIRE
    31 Jul 2018
    Share Share
    Summary Judgment Granted Upholding Formulation Patent Protecting RELISTOR®
    Summary Judgment Granted Upholding Formulation Patent Protecting RELISTOR®

    https://www.prnewswire.com/news-releases/summary-judgment-granted-upholding-the-validity-of-formulation-patent-protecting-relistor-injection-300641653.html

    PR NEWSWIRE
    02 May 2018
    Share Share
    Mylan Pharm’s Generic Methylnaltrexone Bromide Receives Tentative Approval In US
    Mylan Pharm’s Generic Methylnaltrexone Bromide Receives Tentative Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208594

    FDA
    26 Dec 2017
    Share Share
    Mylan Labs Generic Methylnaltrexone Bromide Receives Approval In US
    Mylan Labs Generic Methylnaltrexone Bromide Receives Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208592

    FDA
    06 May 2017
    Share Share
    Valeant touts Salix salesforce scale-up amid rumors of mass rep exit
    Valeant touts Salix salesforce scale-up amid rumors of mass rep exit

    http://www.fiercepharma.com/pharma/valeant-touts-salix-salesforce-scale-up-amid-rumors-mass-rep-exit

    Carly Helfand FIERCE PHARMA
    27 Feb 2017
    Share Share
    Purdue inks Shionogi collab on constipation med as it awaits FDA approval
    Purdue inks Shionogi collab on constipation med as it awaits FDA approval

    http://www.fiercebiotech.com/biotech/purdue-inks-shionogi-collab-constipation-med-as-it-awaits-fda-approval

    Ben Adams FIERCE BIOTECH
    19 Dec 2016
    Share Share
    How much can a new EVP help Valeant's badly battered derm unit?
    How much can a new EVP help Valeant's badly battered derm unit?

    http://www.fiercepharma.com/marketing/how-much-can-a-new-evp-help-valeant-s-badly-battered-derm-unit

    Carly Helfand FIERCE PHARMA
    14 Dec 2016
    Share Share
    Valeant looks to revive Xifaxan with primary care sales effort. Will it work?
    Valeant looks to revive Xifaxan with primary care sales effort. Will it work?

    http://www.fiercepharma.com/marketing/valeant-looks-to-revive-xifaxan-primary-care-sales-effort-will-it-work

    Carly Helfand FIERCE PHARMA
    02 Dec 2016
    Share Share
    Valeant Said to Keep Salix After Takeda Deal Falls Apart
    Valeant Said to Keep Salix After Takeda Deal Falls Apart

    https://www.bloomberg.com/news/articles/2016-11-30/valeant-said-to-plan-to-keep-salix-after-takeda-deal-falls-apart

    Jared S Hopkins BLOOMBERG
    01 Dec 2016
    Share Share
    Valeant Announces Initiation Of A Primary Care Sales For Xifaxan & Relistor
    Valeant Announces Initiation Of A Primary Care Sales For Xifaxan & Relistor

    http://www.prnewswire.com/news-releases/valeant-announces-the-initiation-of-a-primary-care-sales-force-for-xifaxan-and-relistor-300369978.html

    PR NEWSWIRE
    29 Nov 2016
    Share Share
    Valeant And Progenics Announce The U.S. Commercial Launch
    Valeant And Progenics Announce The U.S. Commercial Launch

    http://www.prnewswire.com/news-releases/valeant-and-progenics-announce-the-us-commercial-launch-of-fda-approved-relistor-tablets-300323190.html

    PR NEWSWIRE
    06 Sep 2016
    Share Share
    Valeant Gets FDA OK for Anticonstipation Tablets Developed by Progenics
    Valeant Gets FDA OK for Anticonstipation Tablets Developed by Progenics

    http://www.wsj.com/articles/valeant-gets-fda-ok-for-anticonstipation-tablets-developed-by-progenics-1468974726

    JOSH BECKERMAN WALL STREET JOURNAL
    19 Jul 2016
    Share Share
    FDA Appoved NDA For Salix Pharms' Relistor to Treat Opoid Induced Constipation
    FDA Appoved NDA For Salix Pharms' Relistor to Treat Opoid Induced Constipation

    https://www.pharmacompass.com/pdf/news/fda-appoved-nda-for-salix-pharms-relistor-to-treat-opoid-induced-constipation-1469261946.pdf

    FDA
    19 Jul 2016
    Share Share
    Sobi gains commercial rights from Pharma Swiss
    Sobi gains commercial rights from Pharma Swiss

    http://nordiclifescience.org/sobi-gains-commercial-rights-pharma-swiss/

    Malin Anderson NORDIC LIFE SCIENCE
    07 Jan 2016
    Share Share
    Valeant And Progenics Announce FDA Acceptance Of NDA Submission For Oral RELISTOR®
    Valeant And Progenics Announce FDA Acceptance Of NDA Submission For Oral RELISTOR®

    http://www.prnewswire.com/news-releases/valeant-and-progenics-announce-fda-acceptance-of-nda-submission-for-oral-relistor-300138864.html

    PR NEWS WIRE
    08 Sep 2015
    Share Share
    Valeant, Progenics file Relistor pill in the US
    Valeant, Progenics file Relistor pill in the US

    http://www.pharmatimes.com/Article/15-06-24/Valeant_Progenics_file_Relistor_pill_in_the_US.aspx

    Selina Mckee PHARMA TIMES
    24 Jun 2015
    Share Share
    Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 April 2015
    Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 April 2015

    http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/04/news_detail_002310.jsp&mid=WC0b01ac058004d5c1

    EMA
    24 Apr 2015
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search